Interaction with FcγRIIB Is Critical for the Agonistic Activity of Anti-CD40 Monoclonal Antibody

被引:191
作者
White, Ann L. [1 ]
Chan, H. T. Claude [1 ]
Roghanian, Ali [1 ]
French, Ruth R. [1 ]
Mockridge, C. Ian [1 ]
Tutt, Alison L. [1 ]
Dixon, Sandra V. [1 ]
Ajona, Daniel [1 ]
Verbeek, J. Sjef [2 ]
Al-Shamkhani, Aymen [1 ]
Cragg, Mark S. [1 ]
Beers, Stephen A. [1 ]
Glennie, Martin J. [1 ]
机构
[1] Univ Southampton, Fac Med, Div Canc Sci, Southampton SO16 6YD, Hants, England
[2] Leiden Univ, Med Ctr, Dept Human Genet, NL-2333 ZA Leiden, Netherlands
关键词
C-RECEPTOR POLYMORPHISMS; T-CELL TOLERANCE; IN-VIVO; CD20; IMMUNOTHERAPY; CD40; PATHWAY; B-CELLS; LYMPHOMA; CANCER; THERAPY; TUMOR;
D O I
10.4049/jimmunol.1101135
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
A high activatory/inhibitory Fc gamma R binding ratio is critical for the activity of mAb such as rituximab and alemtuzumab that attack cancer cells directly and eliminate them by recruiting immune effectors. Optimal Fc gamma R binding profiles of other anti-cancer mAb, such as immunostimulatory mAb that stimulate or block immune receptors, are less clear. In this study, we analyzed the importance of isotype and Fc gamma R interactions in controlling the agonistic activity of the anti-mouse CD40 mAb 3/23. Mouse IgG1 (m1) and IgG2a (m2a) variants of the parental 3/23 (rat IgG2a) were engineered and used to promote humoral and cellular responses against OVA. The mouse IgG1 3/23 was highly agonistic and outperformed the parental Ab when promoting Ab (10-100-fold) and T cell (OTI and OTII) responses (2- to >10-fold). In contrast, m2a was almost completely inactive. Studies in Fc gamma R knockout mice demonstrated a critical role for the inhibitory Fc gamma RIIB in 3/23 activity, whereas activatory Fc gamma R (Fc gamma RI, -III, and -IV) was dispensable. In vitro experiments established that the stimulatory effect of Fc gamma RIIB was mediated through Ab cross-linking delivered in trans between neighboring cells and did not require intracellular signaling. Intriguingly, activatory Fc gamma R provided effective cross-linking of 3/23 m2a in vitro, suggesting the critical role of Fc gamma RIIB in vivo reflects its cellular distribution and bioavailability as much as its affinity for a particular Ab isotype. In conclusion, we demonstrate an essential cross-linking role for the inhibitory Fc gamma RIIB in anti-CD40 immunostimulatory activity and suggest that isotype will be an important issue when optimizing reagents for clinical use. The Journal of Immunology, 2011, 187: 1754-1763.
引用
收藏
页码:1754 / 1763
页数:10
相关论文
共 50 条
[31]   Inhibitory Fcγ Receptor Engagement Drives Adjuvant and Anti-Tumor Activities of Agonistic CD40 Antibodies [J].
Li, Fubin ;
Ravetch, Jeffrey V. .
SCIENCE, 2011, 333 (6045) :1030-1034
[32]   Phase I Study of the Humanized Anti-CD40 Monoclonal Antibody Dacetuzumab in Refractory or Recurrent Non-Hodgkin's Lymphoma [J].
Advani, Ranjana ;
Forero-Torres, Andres ;
Furman, Richard R. ;
Rosenblatt, Joseph D. ;
Younes, Anas ;
Ren, Hong ;
Harrop, Kate ;
Whiting, Nancy ;
Drachman, Jonathan G. .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (26) :4371-4377
[33]   Development and characterisation of monoclonal antibodies specific for the murine inhibitory FcγRIIB (CD32B) [J].
Williams, Emily L. ;
Tutt, Alison L. ;
French, Ruth R. ;
Chan, H. T. Claude ;
Lau, Betty ;
Penfold, Christine A. ;
Mockridge, C. Ian ;
Roghanian, Ali ;
Cox, Kerry L. ;
Verbeek, J. Sjef ;
Glennie, Martin J. ;
Cragg, Mark S. .
EUROPEAN JOURNAL OF IMMUNOLOGY, 2012, 42 (08) :2109-2120
[34]   Agonistic Antibody to CD40 Boosts the Antitumor Activity of Adoptively Transferred T Cells In Vivo [J].
Liu, Chengwen ;
Lewis, Carol M. ;
Lou, Yanyan ;
Xu, Chunyu ;
Peng, Weiyi ;
Yang, Yan ;
Gelbard, Alexander H. ;
Lizee, Gregory ;
Zhou, Dapeng ;
Overwijk, Willem W. ;
Hwu, Patrick .
JOURNAL OF IMMUNOTHERAPY, 2012, 35 (03) :276-282
[35]   The efficacy of tumor debulking surgery is improved by adjuvant immunotherapy using imiquimod and anti-CD40 [J].
Khong, Andrea ;
Cleaver, Amanda L. ;
Alatas, Muhammad Fahmi ;
Wylie, Ben C. ;
Connor, Theresa ;
Fisher, Scott A. ;
Broomfield, Steve ;
Lesterhuis, Willem J. ;
Currie, Andrew J. ;
Lake, Richard A. ;
Robinson, Bruce W. .
BMC CANCER, 2014, 14
[36]   ENHANCEMENT OF IGE PRODUCTION BY ANTI-CD40 ANTIBODY IN ATOPIC-DERMATITIS [J].
RENZ, H ;
BRODIE, C ;
BRADLEY, K ;
LEUNG, DYM ;
GELFAND, EW .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1994, 93 (03) :658-668
[37]   Distinct Apoptotic Signaling Characteristics of the Anti-CD40 Monoclonal Antibody Dacetuzumab and Rituximab Produce Enhanced Antitumor Activity in Non-Hodgkin Lymphoma [J].
Lewis, Timothy S. ;
McCormick, Renee S. ;
Emmerton, Kim ;
Lau, Jeffrey T. ;
Yu, Shang-Fan ;
McEarchern, Julie A. ;
Grewal, Iqbal S. ;
Law, Che-Leung .
CLINICAL CANCER RESEARCH, 2011, 17 (14) :4672-4681
[38]   Multifaceted antitumor responses to activating anti-CD40 antibody therapy combined with immunomodulatory or targeted agents [J].
Weiss, Jonathan M. ;
Wiltout, Robert H. .
ONCOIMMUNOLOGY, 2014, 3 (08)
[39]   A phase 1 study of lucatumumab, a fully human anti-CD40 antagonist monoclonal antibody administered intravenously to patients with relapsed or refractory multiple myeloma [J].
Bensinger, William ;
Maziarz, Richard T. ;
Jagannath, Sundar ;
Spencer, Andrew ;
Durrant, Simon ;
Becker, Pamela S. ;
Ewald, Brett ;
Bilic, Sanela ;
Rediske, John ;
Baeck, Johan ;
Stadtmauer, Edward A. .
BRITISH JOURNAL OF HAEMATOLOGY, 2012, 159 (01) :58-66
[40]   CD40-expressing plasmid induces anti-CD40 antibody and enhances immune responses to DNA vaccination [J].
Xu, Hanqian ;
Zhao, Gan ;
Huang, Xiaoxi ;
Ding, Zheng ;
Wang, Junpeng ;
Wang, Xiao ;
Cheng, Yating ;
Kang, Youmin ;
Wang, Bin .
JOURNAL OF GENE MEDICINE, 2010, 12 (01) :97-106